allogeneic natural killer cells

Phase 3Biologic

allogeneic natural killer cells is one of 96 biologic programs targeting Small Cell Lung Cancer. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Small Cell Lung CancerRecruiting

Acute Lymphoblastic LeukemiaTerminated

Refractory AMLNot yet recruiting

Small Cell Lung CancerPhase 2

Recruiting

Acute Lymphoblastic LeukemiaPreclinical

Terminated

Refractory AMLPhase 3

Not yet recruiting

Competition

Competitive Landscape

163 competitors in Acute Lymphoblastic Leukemia

#DrugCompanyPhaseTrials

Oncovin

Eli Lilly

Phase 3

75 2

Adriamycin

Pfizer

Phase 3

40 3

Elspar

DDutch Childhood Oncology Group

Phase 3

45 4

Cerubidine

EEastern Cooperative Oncology Group

Phase 3

43 5

Oncaspar

SServier

Phase 3

48 6

Wellcovorin

EEastern Cooperative Oncology Group

Phase 3

40 7

Fludara

Sanofi

Phase 3

15 8

Medrol

Pfizer

Phase 3

12 9

Iclusig

Cellcept

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2029

Phase 2Recruiting

Small Cell Lung Cancer

NCT07759856

Q1 2034

Phase 2/3Not yet recruiting

Refractory AML

NCT07157514

Clinical

Trials by Indication[1]

Chronic Lymphocytic Leukemia1 trial

Donor Natural Killer Cell Infusion, Rituximab, Aldesleukin, and Chemotherapy in Treating Patients With Relapsed Non-Hodgkin Lymphoma or Chronic Lymphocytic Leukemia

Terminated·MMasonic Cancer Center, University of Minnesota·Phase 1/2·NCT00625729·6 enrolled

T Cells1 trial

Ph I/II Study of CAR19 Regulatory T Cells (CAR19-tTreg) for R/R CD19+ B-ALL

Withdrawn·MMasonic Cancer Center, University of Minnesota·Phase 1/2·NCT05114837

Melanoma1 trial

Aldesleukin With or Without Vaccine Therapy in Treating Patients With Stage IV Melanoma

Completed·MMasonic Cancer Center, University of Minnesota·Phase 2·NCT00726739·21 enrolled

Metastatic1 trial

Phase II Study of Allo LMI Vaccine With IL-2 for Stable Metastatic Breast Ca

Terminated·MMasonic Cancer Center, University of Minnesota·Phase 2·NCT00784524·14 enrolled

Acute Leukemia1 trial

Clofarabine, Cyclophosphamide and Etoposide for Minimal Residual Disease Positive Acute Leukemia

Withdrawn·MMasonic Cancer Center, University of Minnesota·Phase 2·NCT01677949

4 more indications

Acute Lymphoblastic Leukemia1 trial

Busulfan and Cyclophosphamide Followed By ALLO BMT

Terminated·MMasonic Cancer Center, University of Minnesota·N/A·NCT01685411·5 enrolled

Refractory AML1 trial

Radioimmunotherapy Conditioning With 131I- Apamistamab for Allogeneic Transplant in Relapse/Refractory AML

Not yet recruiting·AActinium Pharmaceuticals·Phase 2/3·NCT07157514·306 enrolled

Ovarian Cancer1 trial

Allogeneic Natural Killer Cells in Patients With Recurrent Ovarian Cancer, Fallopian Tube, and Primary Peritoneal Cancer

Terminated·MMasonic Cancer Center, University of Minnesota·Phase 2·NCT00652899·14 enrolled

Small Cell Lung Cancer1 trial

A Randomized, Controlled, Open and Exploratory Clinical Trial of Immunization Combined With Allogeneic NK Cells in the Immune Maintenance Stage After First-line Treatment of Extensive Small Cell Lung Cancer

Recruiting·TTianjin First Central Hospital·Phase 2·NCT07759856·42 enrolled

Sources

References

[1]
ClinicalTrials.gov — 9 trial records for allogeneic natural killer cells. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — allogeneic natural killer cells compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for allogeneic natural killer cells. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Actinium Pharmaceuticals company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 3[1]
Company: AActinium Pharmaceuticals

allogeneic natural killer cells

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2029

Q1 2034

Trials by Indication[1]

Chronic Lymphocytic Leukemia1 trial

T Cells1 trial

Melanoma1 trial

Metastatic1 trial

Acute Leukemia1 trial

Acute Lymphoblastic Leukemia1 trial

Refractory AML1 trial

Ovarian Cancer1 trial

Small Cell Lung Cancer1 trial

References

Drug Info

Quick Facts

Related News